Atypical antipsychotic drugs have their merits

The Lancet

Volumn 373, Issue 9668, 2009, Pages 1007-

  Meltzer, Herbert Y ^a  

^a Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; PALIPERIDONE; PROLACTIN; RISPERIDONE; SEROTONIN 2 ANTAGONIST;

DRUG ANTAGONISM; DRUG RECEPTOR BINDING; LETTER; PARKINSONISM; PRIORITY JOURNAL; RISK FACTOR; SUICIDE; TARDIVE DYSKINESIA;

EID: 62349132103     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60606-1     Document Type: Letter

References (5)

1. Tyrer P., and Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 373 (2009) 4-5
2. Meltzer H.Y. An atypical compound by any other name is still an atypical. Psychopharmacology 148 (2000) 16-19
3. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R., and Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 50 (2005) 703-714
4. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1159-1172
5. Meltzer H.Y., Bobo W.V., Roy A., et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69 (2008) 274-285